On February 13, 2019 Achilles Therapeutics ("Achilles"), a biopharmaceutical company developing personalised cancer immunotherapies, reported the approval by the UK Medicines and Healthcare products Regulatory Agency (MHRA) of its Clinical Trial Application (CTA) to conduct a Phase I/II study using clonal neoantigen targeting T cells (cNeT) in patients with metastatic or recurrent melanoma (Press release, Achilles Therapeutics, FEB 13, 2019, View Source [SID1234533294]). The study is expected to enrol the first patient later in 2019.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"To have received our second CTA approval in as many weeks is highly encouraging," said Dr Iraj Ali, CEO of Achilles Therapeutics. "We look forward to bringing this potentially transformative treatment option into the clinic later this year."

Professor James Larkin, Consultant Medical Oncologist at The Royal Marsden and Reader at the Institute of Cancer Research, said: "The Achilles approach to leveraging the leading science in tumour evolution to tackling solid tumours using cNeT has the potential to change the immune-oncology space and bring life-changing treatment options to patients. We look forward to the start of clinical development."

Achilles is developing personalised T cell therapies for solid tumours targeting clonal neoantigens: protein markers unique to each patient that are present on the surface of all cancer cells. Using its PELEUS bioinformatics platform, Achilles can identify clonal neoantigens from each patient’s unique tumour profile which are present on every cancer cell. Achilles uses its proprietary process to manufacture T cells (cNeT) which exquisitely target a specific set of clonal neoantigens in each patient. Targeting multiple clonal neoantigens that are present on all cancer cells, but not on healthy cells, reduces the risk that new mutations can induce immune evasion and therapeutic resistance, and allows individualised treatments to target and destroy tumours without harming healthy tissue.

On February 13, 2019 Doer Biologics reported in January 2019, Doer Biologics has closed tens of millions RMB in its first financing (Press release, Doer Biologics, FEB 13, 2019, View Source [SID1234656201]). The Series A round was led by Kaitai Capital, with participation from Hangzhou Bairui Investment Company. Doer Biologics devotes to the development of multi-domain innovative biopharmaceutics, focusing on unmet clinical needs. Based on its MultipleBody and XLong long acting technology platforms, Doer biologics has developed DR10619, DR30121 and other products, which are significantly competitive in the field of NASH and AMD. Its first financing will certainly facilitate the progress of its products to IND application.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On February 13, 2019 Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF)("CURE" or the "Company") reported that it has arranged a non-brokered private placement of 6,976,745 million units at 43 cents per unit for gross proceeds of $3 Million or more, depending on investor interest (Press release, Biocure Technology, FEB 13, 2019, View Source [SID1234628757]). Each Unit will entitle the holder to receive one common share of the Company (each a "Common Share") and one Full Warrant ("Warrants") exercisable for 24 Months for CDN$0.86. Each warrant is subject to accelerated expiry provisions, such that if at any time after the expiry of any resale restriction governing the subscribed shares, the corporation’s common shares trade on the Canadian Securities Exchange at or above a volume-weighted average trading price of $1.29 per common share for 10 consecutive trading days, the company may give notice to the holders that each warrant will expire 30 days from the date of providing such notice.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Finder’s fees or commissions may be payable by the Company in connection with this Private Placement.

The net proceeds from the non-brokered private placement are intended to be used for general working capital and research and development.

On February 13, 2019 Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), ("Onxeo" or "the Company"), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, in particular against rare or resistant cancers, reported that results of five preclinical study supporting the differentiated profile of AsiDNA, its first-in-class DNA Damage Response (DDR) inhibitor, including insights into the compound’s unique mechanism of action, will be presented at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting being held March 29 – April 3, 2019, in Atlanta, GA, USA (Press release, Onxeo, FEB 13, 2019, View Source [SID1234533278]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Françoise Bono, PhD, Chief Scientific Officer, commented: "We are thrilled to have had five AsiDNA-related abstracts accepted for presentation at this prestigious meeting of oncology, including 2 abstracts resulting from our long-standing collaboration with Institut Curie, an internationally recognized research institution. The study to be presented notably support the absence of the emergence of resistance to AsiDNA after repeated treatments and the abrogation of acquired resistance to PARP inhibitors when administered in combination with AsiDNA, two properties that make AsiDNA so distinctive and sustain its promising potential for future utilization in clinic. New data also provide valuable insights into the underlying mechanisms supporting these unique outcomes and their potential benefits in oncology. Furthermore, we have identified predictive biomarkers of sensitivity to AsiDNA, a strong advantage to optimize its clinical development and which could, ultimately, open the way to personalized medicine with AsiDNA. Lastly, these results expand the solid preclinical package on AsiDNA, further support the strong rationale for its ongoing development in the clinical setting and confirm its interest and its value in our company portfolio."

Titles of the five abstracts to be presented during poster sessions are:

AsiDNA, a targeted therapy with no acquired resistance
AsiDNA abrogates acquired resistance to PARP inhibitors
Molecular analysis of the mechanism of action of AsiDNA brings new clues on DNA damage response regulation
Development of a biomarker-driven patient selection strategy for AsiDNA treatment (in collaboration with Institut Curie)
AsiDNA, a novel DNA repair inhibitor to sensitize aggressive medulloblastoma subtypes (Institut Curie)
Details on the date, time and location of the sessions during the congress will be provided when available.

On February 13, 2019 Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body’s immune system to fight cancer, reported that Dr. Amit Kumar, its President and CEO, will be presenting on a panel discussion at Moffitt Cancer Center’s 13th Annual Business of Biotech Conference being held on February 22, 2019 (Press release, Anixa Biosciences, FEB 13, 2019, View Source [SID1234533295]). The panel titled, "Navigating FDA Approvals for Cell Therapy" will focus on regulatory aspects of developing CAR-T and other cell therapies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition to Dr. Kumar, other participants on the panel will include executives from Atara Biotherapeutics, Inc., Intellia Therapeutics, Inc., and Iovance Biotherapeutics, Inc.

The Business of Biotech Conference is an annual event held by Moffitt Cancer Center that brings together investors and experts from academia and industry interested in learning about the most advanced technologies in cancer research. For those interested in attending, please review the agenda and register here: View Source

Dr. Kumar stated, "I am pleased to be attending and presenting at this conference. Moffitt Cancer Center is one of the top cancer centers in the world and a critical partner for Anixa. I am also pleased to be participating with colleagues from other leading CAR-T and cell therapy companies."